This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cholib
  • /
  • Simvastatin in Secondary Progressive Multiple Scle...
Clinical trial

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

Read time: 3 mins
Last updated:1st Mar 2019
Identifier: NCT03896217

Multiple sclerosis (MS) is a neurological condition which is a common cause of disability in young people. It is thought to be an autoimmune condition, where the body's immune system begins to attack itself. The cause of MS is unknown but is thought to be a mix of genetic and environmental factors. There are treatments available for early stages of MS, but the later stage known as Secondary Progressive MS (SPMS) has no current treatment.

Statins are a safe treatment traditionally used to reduce cholesterol levels. However, statins also have other effects which could reduce the progression of SPMS, such as effects on the immune system and circulation. A recent study (Chataway et al., 2014) showed that treatment with high-dose simvastatin, a type of statin, reduced the progression of SPMS but no effect on the immune system was seen. It is possible that simvastatin does not treat the immune system but improves how the blood and blood vessels in the brain work in this disease.

The purpose of the clinical trial is to test how Simvastatin (80mg/day) may slow down disease progression in people living with SPMS compared to placebo (dummy pill). Participants will receive either Simvastatin or placebo and will be asked to take 2 tablets daily, for up to 17 weeks.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage
Estimated Study Start Date: March 2019
Estimated Primary Completion Date: January 2021
Estimated Study Completion Date: January 2021

- Active Comparator:
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-03-29
Study type(s) Interventional
Expected enrolment 40
Study start date 2019-03-01
Estimated primary completion date 2021-01-01

View full details